A Nomogram for Predicting Survival in Advanced Non-Small-Cell Lung Carcinoma Patients: A Population-Based Study.

IF 1.8 4区医学 Q3 ONCOLOGY

Cancer Investigation Pub Date : 2023-09-01 DOI:10.1080/07357907.2023.2241547

Bo Yang, Mengmeng Teng, Haisheng You, Yalin Dong, Siying Chen

引用次数: 0

Abstract

Non-small-cell lung cancer (NSCLC) remains the most common malignant cancer. We identified 43140 advanced NSCLC patients from the SEER database to develop and validate a new prognostic model. The prognostic performance was evaluated by P value, concordance index, net reclassification index, integrated discrimination improvement, and decision curve analysis. The following variables were contained in the final prognostic model: age, sex, race, TNM stage, and grade and treatment options. Compared to the AJCC staging system, this prognostic model is conducive to the implementation of individualized clinical treatment schemes and can be an important part of the precise medical care of NSCLC tumors.

查看原文本刊更多论文

预测晚期非小细胞肺癌患者生存的Nomogram:一项基于人群的研究。

非小细胞肺癌(NSCLC)仍然是最常见的恶性肿瘤。我们从SEER数据库中确定了43140例晚期NSCLC患者，以开发和验证一种新的预后模型。采用P值、一致性指数、净重分类指数、综合判别改善和决策曲线分析评价预后。以下变量包含在最终的预后模型中:年龄、性别、种族、TNM分期、分级和治疗方案。与AJCC分期系统相比，该预后模型有利于实施个体化临床治疗方案，可成为NSCLC肿瘤精准医疗护理的重要组成部分。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Investigation 医学-肿瘤学

CiteScore

3.80

自引率

4.20%

发文量

审稿时长

8.5 months

期刊介绍： Cancer Investigation is one of the most highly regarded and recognized journals in the field of basic and clinical oncology. It is designed to give physicians a comprehensive resource on the current state of progress in the cancer field as well as a broad background of reliable information necessary for effective decision making. In addition to presenting original papers of fundamental significance, it also publishes reviews, essays, specialized presentations of controversies, considerations of new technologies and their applications to specific laboratory problems, discussions of public issues, miniseries on major topics, new and experimental drugs and therapies, and an innovative letters to the editor section. One of the unique features of the journal is its departmentalized editorial sections reporting on more than 30 subject categories covering the broad spectrum of specialized areas that together comprise the field of oncology. Edited by leading physicians and research scientists, these sections make Cancer Investigation the prime resource for clinicians seeking to make sense of the sometimes-overwhelming amount of information available throughout the field. In addition to its peer-reviewed clinical research, the journal also features translational studies that bridge the gap between the laboratory and the clinic.